-
In this conversation with a16z General Partner Julie Yoo, Makary and Yoo discuss what price transparency in the healthcare system could really do; how we can "steer" towards the good physicians who are not just highly skilled, but make the right judgment calls based on need and holistic health, not cost; how we might distinguish between high value and low value through medical appropriateness; and how we might gain clinical wisdom from other kinds of scientific discovery beyond randomized controls, especially during the wartime protocol of COVID-19.
-
Novartis recently announced what is now the most expensive medicine in history: Zolgensma, a newly-approved gene therapy to treat a devastating disease called Somatic Muscular Atrophy, or SMA, will have a price tag of $2...
-
The advent of new gene and cell therapies are beginning to approach that holy grail of medicine—that of a possible cure. But they are also more expensive than any medicines ever sold before. In this episode, MIT econom...
-
Since the startup (and founder) journey doesn't go neatly linear from technical to product to sales, tightening one knob (whether engineering or marketing or pricing & packaging) creates slack in one of the other knobs, which demands turning to yet another knob. So how do you know what knob to focus on and when? How do you build the right team for the right play and at the right time?
-
The “death of retail” in the face of e-commerce and tech disruption is a very real phenomenon, but what about the flip side of that story — that is, retail thriving despite all odds?
-
The purpose of category creation, argue the guests in this episode of the podcast, isn’t just about making a dent in the way companies work and changing what people do every day… it’s about setting the ...
-
The route by which you distribute your product to customers—i.e., the channel—is key, as is the decision whether to partner with others.
-
watch time: 27 minutes